ストックスクリーナーアプリを入手
0.6251
3.77%
-0.0245
アフターアワーズ：
.62
-0.0051
-0.82%
前日終値:
$0.6496
開ける：
$0.64
24時間の取引高:
435.80K
Relative Volume:
0.77
時価総額：
$34.21M
収益：
-
当期純損益:
$-34.88M
株価収益率:
-0.7646
EPS:
-0.8176
ネットキャッシュフロー:
$-32.28M
1週間 パフォーマンス:
-4.42%
1か月 パフォーマンス:
-4.97%
6か月 パフォーマンス:
-40.47%
1年 パフォーマンス:
-53.70%
1日の値動き範囲:
$0.60
$0.64
1週間の範囲:
$0.60
$0.7349
52週間の値動き範囲:
$0.60
$1.915
Pds Biotechnology Corporation Stock (PDSB) Company Profile
名前
Pds Biotechnology Corporation
セクター
電話
800-208-3343
住所
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.6251 | 35.55M | 0 | -34.88M | -32.28M | -0.8176 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-01 | 開始されました | B. Riley Securities | Buy |
| 2021-06-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-09 | 開始されました | Noble Capital Markets | Outperform |
| 2019-10-24 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Pds Biotechnology Corporation (PDSB) 最新ニュース
Will PDS Biotechnology Corporation stock go up in YEARPortfolio Profit Report & Safe Entry Momentum Tips - baoquankhu1.vn
Block Trades: Can PDS Biotechnology Corporation stock outperform in a bear market2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
PDSB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PDS Biotechnology (PDSB) CEO receives 548,782-share stock option award - Stock Titan
[Form 4] PDS Biotechnology Corp Insider Trading Activity - Stock Titan
PDS Biotechnology (PDSB) awards 150,000 stock options to Chief Scientific Officer - Stock Titan
PDS Biotechnology (PDSB) CMO receives grant of 300,000 stock options - Stock Titan
PDS Biotechnology grants 300,000 options to executive | PDSB SEC FilingForm 4 - Stock Titan
PDS Biotechnology (PDSB) director Ilian Iliev receives grant of 54,876 stock options - Stock Titan
PDS Biotechnology director granted 54,876 options | PDSB SEC FilingForm 4 - Stock Titan
Director option grant at PDS Biotechnology (PDSB) totals 54,876 options - Stock Titan
PDS Biotechnology (PDSB) director awarded 54,876 stock options in new grant - Stock Titan
PDS Biotechnology receives Nasdaq notice for minimum bid price deficiency - Investing.com Australia
Nasdaq warns PDS Biotechnology (NASDAQ: PDSB) on $1.00 bid price rule - Stock Titan
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB) - The Wall Street Transcript
PDS Biotech Announces Amended Protocol for Phase 3 Trial - National Today
PDSB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
PDS Biotech (NASDAQ: PDSB) highlights HPV16 trial gains and pipeline - Stock Titan
Will PDS Biotechnology Corporation stock outperform Dow Jones indexMarket Movers & Consistent Profit Focused Trading Strategies - mfd.ru
PDS Biotechnology Amends Late-Stage Trial for PDS0101 to Support Accelerated Approval Pathway in HPV16-Positive Head and Neck Cancer - marketscreener.com
PDS Biotech amends Phase 3 trial to add accelerated approval path - Investing.com
LiveRamp Holdings, Inc. has announced a partnership with Scowtt - Bitget
Nucor has announced that Jack Sullivan has been promoted to Chief Financial Officer, Treasurer, and Executive Vice President of the company. - Bitget
PDS Biotechnology Corporation (PDS Biotech) recently announced that it has made significant amendments to the study protocol of its Phase III clinical trial, Versatile-003. - Bitget
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - The Manila Times
Cancer trial shift seeks faster PDS0101 bid for HPV16 head and neck patients - Stock Titan
Published on: 2026-02-19 10:39:09 - baoquankhu1.vn
PDS Biotechnology Approaches Critical Regulatory and Clinical Milestones - AD HOC NEWS
Is PDS Biotechnology Corporation likely to announce a buybackQuarterly Trade Review & AI Driven Price Predictions - mfd.ru
Can PDS Biotechnology Corporation stock outperform in a bear marketWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
PDS Biotech’s Big Bet Rides On Two Trial Readouts - Finimize
Growth Review: Can PDS Biotechnology Corporation stock outperform in a bear marketJuly 2025 Update & Weekly High Momentum Picks - baoquankhu1.vn
PDS Biotechnology: Regulatory Agreement Paves Way for Accelerated Cancer Therapy Review - AD HOC NEWS
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study By Investing.com - Investing.com South Africa
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study - Investing.com Nigeria
PDS Biotechnology Corporation Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - marketscreener.com
PDS Biotechnology Corporation Reports 9.6 Months Median Progression-Free Survival from NCI-Led Study of PDS01ADC in Advanced Prostate Cancer - Quiver Quantitative
PDS Biotech Announces Presentation of Preliminary Results - GlobeNewswire
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - The Manila Times
PDS Biotech secures patent for cancer immunotherapy PDS0101 By Investing.com - Investing.com Nigeria
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection - TipRanks
PDS Biotech secures patent for cancer immunotherapy PDS0101 - Investing.com
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - The Manila Times
New PDS0101 patent extends U.S. market protection toward 20 years - Stock Titan
Aug Macro: Can PDS Biotechnology Corporation stock outperform in a bear market2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Miss: Can STRW maintain sales growthMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Growth Value: Is PDS Biotechnology Corporation trading at a discount - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
PDS Biotechnology Corporation (PDSB) stock: surges as FDA protocol amendment aims for accelerated approval - parameter.io
PDS Biotech stock soars after FDA meeting provides accelerated approval path By Investing.com - Investing.com South Africa
Pds Biotechnology Corporation (PDSB) 財務データ
収益
当期純利益
現金流量
EPS
1.20%
0.06%
大文字化:
|
ボリューム (24 時間):